Last viewed: ALNY


Prices are updated after-hours



nasdaq:ALNY Alnylam Pharmaceuticals, Inc.

ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-29.2% 1m) (-15.3% 1y) (0.0% 2d) (-2.9% 3d) (-4.9% 7d) (NaN% volume)
http://www.alnylam.com
Sec Filling | Patents | 1323 employees

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Drugs
GIVLAARI (givosiran sodium)
Onpattro (patisiran)
OXLUMO (lumasiran)

add to today's watch list email alert is off




glass   genetic   msa   treatment  

Press-releases


Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
SNY | News 1 d | $51.79 | twitter stocktwits trandingview |
Health Technology
| | O: -1.41% H: 0.0% C: 0.0%
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: -2.91% H: 0.0% C: 0.0%
STOK | News | $19.07 | twitter stocktwits trandingview |
Health Technology
| | O: -2.33% H: 0.0% C: 0.0%

era technology therapeutics
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: -2.0% H: 0.0% C: 0.0%

rare ces era technology therapeutics disease
At 17.42% CAGR, Oligonucleotide Synthesis Market Size is Expected to Reach USD 22584.1 Million in 2028, says Brandessence Market Research
Published: 2022-01-17 (Crawled : 13:30) - prnewswire.com
SRPT | $71.875 | twitter stocktwits trandingview |
Health Technology

DHR | $287.03 | twitter stocktwits trandingview |
Health Technology

ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology

BIIB | $230.81 | twitter stocktwits trandingview |
Health Technology

IONS | News | $30.75 | twitter stocktwits trandingview |
Health Technology

TWST | News | $55.21 | twitter stocktwits trandingview |
Health Technology

ce mark leo research
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
Published: 2022-01-14 (Crawled : 12:30) - biospace.com/
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: 1.47% H: 0.0% C: 0.0%

results phase 3
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
Published: 2022-01-11 (Crawled : 15:00) - biospace.com/
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: -0.31% H: 0.0% C: 0.0%


Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: -3.19% H: 0.0% C: -3.32%

novartis ces announces collaboration era liver therapy collaboration
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: 0.34% H: 0.0% C: 0.0%

ces
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-03 (Crawled : 13:00) - biospace.com/
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: 0.96% H: 0.0% C: 0.0%

health thc conference presentation j.p. morgan healthcare conference
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | News | $88.91 | twitter stocktwits trandingview |
Health Technology
| | O: -0.55% H: 0.99% C: 0.92%
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: -5.24% H: 2.44% C: -0.93%

leqvio fda fda approval era approval
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News 1 d | $51.79 | twitter stocktwits trandingview |
Health Technology
| | O: -0.59% H: 1.12% C: 0.93%
ALNY | News | $141.27 | twitter stocktwits trandingview |
Health Technology
| | O: -5.24% H: 2.44% C: -0.93%

alzheimer treatment application era disease
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying